SWOG clinical trial number
SWOG-8821
Study of Continuous Infusion Recombinant Interleukin-2 (rIL-2) in Patients with Refractory Carcinoma of the Breast
Closed
Phase
Accrual
3%
Abbreviated Title
Study of Continuous Infusion Recombinant Interleukin-2 (rIL-2) in Patients with Refractory Carcinoma of the Breast
Activated
05/15/1990
Closed
08/01/1991